Silence Therapeutics (NASDAQ:SLN) Stock Falls 5.1% - What's Next?

Key Points

• Silence Therapeutics shares fell 5.1% to approximately $10.10, with trading volume down 91% from the average daily level.
• Analyst sentiment remains generally positive, with an average rating of “Moderate Buy” and an average price target of $53.50, despite one sell rating.
• The company missed its latest quarterly EPS estimate, reporting a loss of $0.26 per share versus the expected $0.14 loss; institutional investors own 98.73% of its stock.

Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN - Get Free Report)'s stock price dropped 5.1% on Monday. The stock traded as low as $10.23 and last traded at $10.0960. Approximately 51,739 shares changed hands during trading, a decline of 91% from the average daily volume of 592,301 shares. The stock had previously closed at $10.64.

Analyst Ratings Changes

A number of equities research analysts have commented on SLN shares. Weiss Ratings restated a "sell (d-)" rating on shares of Silence Therapeutics in a research report on Friday, July 17th. HC Wainwright reiterated a "buy" rating and issued a $75.00 target price on shares of Silence Therapeutics in a report on Wednesday, June 17th. Cantor Fitzgerald started coverage on shares of Silence Therapeutics in a research report on Wednesday, June 24th. They issued an "overweight" rating for the company. Finally, Morgan Stanley boosted their price objective on shares of Silence Therapeutics from $25.00 to $32.00 and gave the company an "overweight" rating in a research report on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $53.50.

Silence Therapeutics Price Performance

The business has a 50 day simple moving average of $12.75 and a 200 day simple moving average of $9.36. The stock has a market cap of $626.79 million, a PE ratio of -8.13 and a beta of 1.45.

Silence Therapeutics (NASDAQ:SLN - Get Free Report) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.12). Silence Therapeutics had a negative net margin of 8,943.86% and a negative return on equity of 106.94%. As a group, sell-side analysts forecast that Silence Therapeutics PLC Sponsored ADR will post -1.03 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. 5AM Venture Management LLC bought a new position in shares of Silence Therapeutics in the 2nd quarter valued at approximately $5,228,676. Ishara Investments LP bought a new stake in Silence Therapeutics during the fourth quarter valued at about $1,459,000. ADAR1 Capital Management LLC grew its position in shares of Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company's stock valued at $907,000 after purchasing an additional 148,514 shares during the last quarter. Seven Fleet Capital Management LP acquired a new stake in shares of Silence Therapeutics in the fourth quarter valued at about $897,000. Finally, SG Americas Securities LLC increased its stake in shares of Silence Therapeutics by 11.8% in the first quarter. SG Americas Securities LLC now owns 286,698 shares of the company's stock worth $1,511,000 after purchasing an additional 30,358 shares during the period. Institutional investors and hedge funds own 98.73% of the company's stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use RNA interference (RNAi) to selectively reduce the production of disease-causing proteins. The company's approach is designed to act at the genetic level by targeting specific messenger RNA molecules before they are translated into proteins.

Silence's research is supported by its proprietary mRNAi GOLD platform, which is intended to enable the development and delivery of small interfering RNA (siRNA) medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.